Renal Cell Carcinoma in the Era of Targeted Therapy and Immunotherapy
Renal cell carcinoma (RCC) is the most common kidney cancer in adults, although its biology and treatment response vary considerably between patients. Clear cell RCC accounts for most cases, while papillary, chromophobe and rarer subtypes require different diagnostic and therapeutic considerations. Advances in molecular research have changed the way clinicians assess tumour risk, select systemic treatment and monitor disease over time.
For Australians, this progress is relevant across public hospitals, private oncology practices and regional cancer services. A patient in Sydney, Melbourne, Brisbane or a remote community may have access to the same evidence-based medicines, but travel, specialist availability, Medicare arrangements and Pharmaceutical Benefits Scheme (PBS) access can influence how care is delivered.
| Treatment approach | Main role | Common considerations |
|---|---|---|
| Surgery | Localised RCC and selected locally advanced disease | Partial or radical nephrectomy, kidney function, surgical expertise |
| VEGF-targeted therapy | Advanced or metastatic RCC | Hypertension, fatigue, diarrhoea, hand-foot syndrome |
| mTOR inhibition | Selected advanced disease | Metabolic effects, mouth ulcers, pneumonitis |
| Immune checkpoint inhibitors | Advanced disease and some adjuvant settings | Immune-related inflammation affecting organs |
| Combination therapy | First-line advanced RCC for many risk groups | Greater response potential with more monitoring needs |
| Active surveillance or ablation | Small renal masses in selected patients | Tumour growth, frailty, renal function and patient preference |
How Kidney Cancer Is Diagnosed
RCC is often discovered incidentally during an ultrasound, CT scan or MRI performed for another reason. Some patients develop blood in the urine, persistent flank discomfort, unexplained weight loss, fever or fatigue, although the classic combination of haematuria, pain and a palpable mass is uncommon in contemporary practice. A contrast-enhanced CT scan is frequently central to diagnosis and staging, while MRI can help when contrast exposure or venous involvement requires closer assessment.
A urologist considers tumour size, location, relationship to blood vessels and collecting structures, kidney function and the health of the opposite kidney. A biopsy may be recommended before ablation, systemic therapy or active surveillance, particularly when imaging cannot reliably distinguish RCC from a benign lesion. Histopathology and, when necessary, molecular testing help define the subtype and expected behaviour.
Surgery And Kidney Preservation
For localised disease, surgery remains the principal potentially curative treatment. Partial nephrectomy removes the tumour while preserving functioning kidney tissue and is preferred when technically suitable, especially for smaller masses or patients at risk of chronic kidney disease. Radical nephrectomy removes the entire kidney and may be necessary for a large, central or locally extensive tumour.
Robotic and laparoscopic techniques are available in major Australian centres, while open surgery still has a role in complex cases. Decisions should be based on cancer control, surgical safety and long-term renal function rather than the appeal of a particular surgical platform. Follow-up commonly includes imaging, blood pressure checks and creatinine or estimated glomerular filtration rate monitoring.
Targeted Medicines And Their Role
Targeted therapy emerged from the discovery that many clear cell RCC tumours are driven by abnormal von Hippel–Lindau, hypoxia-inducible factor and vascular endothelial growth factor pathways. VEGF receptor tyrosine kinase inhibitors, including axitinib, pazopanib, cabozantinib and sunitinib, can restrict tumour blood-vessel development and signalling. Newer agents may inhibit additional pathways involved in tumour growth and resistance.
These medicines are usually taken orally, which can make treatment practical for patients living far from a metropolitan cancer centre. However, convenience does not remove the need for regular review. Blood pressure, liver function, thyroid function, medication interactions and symptoms such as diarrhoea, skin changes and fatigue require active management. PBS listing and local prescribing protocols may affect which option is offered in Australia.
Immunotherapy Changes The Treatment Landscape
Immune checkpoint inhibitors work by releasing brakes on T cells, allowing the immune system to recognise and attack cancer more effectively. Nivolumab, pembrolizumab, ipilimumab and avelumab have been studied in different RCC settings, with combination regimens now important in many patients with advanced disease. The most appropriate treatment depends on International Metastatic RCC Database Consortium risk, tumour features, symptoms, comorbidities and previous therapy.
Immunotherapy can produce durable responses, but it is not suitable for everyone and does not guarantee benefit. Immune-related adverse events may affect the thyroid, bowel, liver, lungs, skin, kidneys or adrenal glands. New diarrhoea, breathlessness, jaundice, severe rash or unusual tiredness should be reported promptly rather than dismissed as ordinary treatment effects. Australian oncology teams generally provide written escalation instructions and coordinate care with general practitioners.
Choosing Combination Treatment
Modern first-line treatment often combines an immune checkpoint inhibitor with another checkpoint inhibitor or a VEGF-directed drug. Combination treatment can improve response rates and progression-free survival compared with older single-agent approaches, yet the balance between benefit and toxicity is individual. A rapidly growing, symptomatic cancer may require a different strategy from a slower-growing tumour in a person with significant cardiovascular or autoimmune disease.
Shared decision-making is particularly important because treatment may continue for months or years. Patients should understand the expected schedule, monitoring requirements, potential dose interruptions and what happens if the cancer progresses. An Australian multidisciplinary team may include a urologist, medical oncologist, radiologist, pathologist, renal physician, oncology nurse and pharmacist, with telehealth helping some regional patients participate in reviews.
Monitoring Response And Managing Resistance
Treatment response is assessed through clinical review, blood tests and repeat imaging, usually with CT of the chest, abdomen and pelvis. A reduction in tumour size is encouraging, but stable disease can also represent meaningful control. Occasionally, immune therapy causes inflammatory enlargement or unusual imaging changes that complicate interpretation, so scans must be considered alongside symptoms and laboratory results.
Cancer cells can adapt, allowing progression after an initial response. Later-line options may include cabozantinib, lenvatinib combined with everolimus, tivozanib or other targeted agents, depending on prior exposure and regulatory access. Clinical trials remain valuable, especially for non-clear-cell RCC, rare molecular subtypes and treatment-resistant disease. Researchers and clinicians can follow developments through Urological Science, a journal covering urology and related clinical research.
Living With Treatment In Australia
Kidney function, cardiovascular health, diabetes, smoking history and weight can influence treatment safety. Stopping smoking, controlling blood pressure, remaining physically active within individual limits and maintaining a balanced diet support general health, although no special diet has been proven to cure RCC. Patients should check supplements and complementary medicines with their treatment team because some products alter drug metabolism or increase bleeding risk.
Information found online varies widely in reliability. A page about cosmetic Botox treatment, for example, is unrelated to kidney cancer and should not be used to guide bladder, renal or oncology decisions. Peer-reviewed sources, specialist cancer services and established organisations provide a safer basis for understanding treatment. The journal information page also explains the publication’s scope and editorial background for readers seeking medical research.
Supportive care may include renal dietetics, exercise physiology, counselling, pain management and palliative care alongside anticancer treatment. Palliative care is appropriate at any stage when symptom control or quality of life needs attention; it does not mean that active cancer treatment has stopped. For Aboriginal and Torres Strait Islander patients, culturally safe care, trusted local health workers and practical support with transport and accommodation can make specialist treatment more accessible.
Research, Trials And Personalised Care
The next phase of RCC treatment is likely to combine clinical risk assessment with tumour genomics, circulating biomarkers and improved imaging. Researchers are investigating ways to identify which patients can safely stop immunotherapy, who is likely to relapse after surgery and how to overcome resistance to checkpoint blockade. Hypoxia-inducible factor-2 alpha inhibitors and novel immune-based combinations are among the approaches shaping the research pipeline.
Patients considering a trial should ask about its purpose, treatment schedule, possible placebo or control groups, travel requirements, costs and access after the study ends. Trial participation is voluntary and should never replace a clear explanation of standard treatment. The urology research portal may offer additional context, but treatment decisions should remain with the qualified clinical team caring for the patient.
Anyone diagnosed with RCC should request a clear pathology report, staging explanation and written treatment plan. Discuss kidney function, fertility where relevant, inherited cancer assessment, medicine access and warning symptoms before treatment begins. In Australia, asking how Medicare, the PBS, private insurance or travel assistance apply to a proposed therapy can prevent avoidable delays.
Speak with a urologist or medical oncologist about the subtype, stage and treatment options that fit the individual clinical picture. Reliable information, prompt reporting of side effects and coordinated follow-up can help patients make informed decisions as renal cell carcinoma care continues to evolve.